Best Menopause & Hormone Care for Women 35+

For most women under 60 and within 10 years of their last period, the benefits of HRT significantly outweigh the risks — this is the current consensus of the North American Menopause Society (NAMS), the British Menopause Society, and the International Menopause Society. Earlier studies that raised concerns used different hormone formulations and populations than what is commonly prescribed today. The risks depend heavily on your personal history, so a menopause-specialist evaluation is the right starting point.

No. Most programs — and most menopause specialists — will consider HRT for women in perimenopause who are experiencing significant symptoms. You do not need to have had 12 months without a period. Symptoms like disrupted sleep, hot flashes, mood changes, and cognitive shifts in the perimenopausal window are valid reasons to discuss treatment.

Midi Health says it works with many PPO plans. Evernow and Gennev also offer commercial insurance coverage for eligible video visits. Coverage depends on the exact plan, state, and clinician, and medication coverage is a separate pharmacy-benefit question. Verify directly with both the service and your insurer before booking.

"Bioidentical" is a marketing term rather than a clinical one. FDA-approved hormone therapies like estradiol patches (Vivelle-Dot, Climara) are chemically identical to the estrogen your body produces — and are technically bioidentical. Compounded "bioidentical" preparations sold by some providers are not FDA-approved and have not been tested the same way. The best question to ask your provider is: "Are these FDA-approved hormones?" not "Are they bioidentical?"

Most women notice improvement in hot flashes and sleep within 2–4 weeks. Full symptom stabilisation — including mood, energy, and cognitive clarity — typically takes 8–12 weeks at therapeutic doses. Vaginal symptoms may improve more slowly, often over 3–6 months of local estrogen therapy.

This depends entirely on your specific history and should be discussed with a menopause-specialist physician, not a general telehealth intake form. For some women with certain cancer histories, local (vaginal) estrogen is considered safe. For most systemic HRT, prior breast cancer and certain clotting disorders are standard contraindications. Any program that issues HRT prescriptions without asking about these should be avoided.